CCND1 and glioma: More importantly, silencing HAS3 or treatment with the anti-CD44 antibodies decreased the levels of the cell cycle-related proteins cyclin B1 and cyclin D1 in glioma cells, and CQ treatment further enhanced this effect (Fig. 5C).